<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03728777</url>
  </required_header>
  <id_info>
    <org_study_id>H-17039503</org_study_id>
    <nct_id>NCT03728777</nct_id>
  </id_info>
  <brief_title>Resveratrol Supplementation in Patients With Mitochondrial Myopathies and Skeletal Muscle Fatty Acid Oxidation Disorders</brief_title>
  <official_title>Resveratrol Supplementation in Patients With Mitochondrial Myopathies and Skeletal Muscle Fatty Acid Oxidation Disorders: A Double-blind, Placebo-controlled, Cross Over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the potential beneficial effects of a daily&#xD;
      supplement of Resveratrol (1000mg/day) on physical ability and on muscle metabolism in&#xD;
      patients with verified mitochondrial myopathy and patients with a verified fatty acid&#xD;
      oxidation defect of VLCAD and CPTII deficiencies. Investigators hypothesize an improved&#xD;
      muscle metabolism, mitochondrial function, fatty acid oxidation and thus improvement of&#xD;
      physical ability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: double-blind, randomized, placebo-controlled, cross-over study.&#xD;
&#xD;
      To ensure enough participants, and due to the risk of a heterogeneous cohort, a cross-over&#xD;
      design is chosen, where participants are their own controls. 10 patients with mitochondrial&#xD;
      myopathy and 10 patients with fatty acid oxidation defects will be included. Eligible&#xD;
      patients will be randomized using a 1:1 assignment ratio to receive placebo or RSV first.&#xD;
      Each treatment will be administered orally twice daily for 8 weeks, followed by a 4 weeks&#xD;
      wash-out, and afterwards a new 8-week treatment period.&#xD;
&#xD;
      During the 20-week trial period, subjects will visit the trial site on five occasions, for&#xD;
      functional assessments (cycle ergometer testing), blood sampling and questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2018</start_date>
  <completion_date type="Actual">October 1, 2019</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>double-blind, randomized, placebo-controlled, cross-over study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>20 weeks</time_frame>
    <description>Decrease in heart rate during constant load cycling exercise.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak oxygen utilization</measure>
    <time_frame>20 weeks</time_frame>
    <description>VO^2max (ml/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty acid oxidation</measure>
    <time_frame>20 weeks</time_frame>
    <description>Fatty acid oxidation will be assessed by stable isotope technique (only for fatty acid oxidation defect disease subgroup)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived exertion</measure>
    <time_frame>20 weeks</time_frame>
    <description>Evaluation of perceived exertion (Borg score) during constant workload cycling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale score</measure>
    <time_frame>20 weeks</time_frame>
    <description>Evaluation of self-rated fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 questionnaire</measure>
    <time_frame>20 weeks</time_frame>
    <description>Evaluation of self-rated daily function scores</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Mitochondrial Myopathies</condition>
  <condition>Fatty Acid Oxidation Defects</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Over the counter supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>Resveratrol supplementation 1000 mg /day or placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Resveratrol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is willing and able to provide written informed consent prior to&#xD;
             participation.&#xD;
&#xD;
          2. Patient is ≥18 and ≤80 years of age at baseline.&#xD;
&#xD;
          3. Patients have genetically verified mitochondrial disorder or a fatty acid oxidation&#xD;
             deficiency (VLCAD/CPTII).&#xD;
&#xD;
          4. Patient has a clinical presentation, signs or symptoms suggestive of myopathy (e.g.,&#xD;
             easy fatigability, exercise intolerance, muscle pain) in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
          5. Patient is ambulatory.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has any prior or current medical conditions that, in the judgment of the&#xD;
             Investigator, would prevent the patient from safely participating in and/or completing&#xD;
             all study requirements.&#xD;
&#xD;
          2. Patient has symptoms of mitochondrial myopathy due to known secondary mitochondrial&#xD;
             dysfunction (e.g., drug-induced myopathy).&#xD;
&#xD;
          3. Patient does not have the cognitive capacity to understand/comprehend and complete all&#xD;
             study assessments.&#xD;
&#xD;
          4. Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Vissing, professor</last_name>
    <role>Study Director</role>
    <affiliation>Copenhangen Neuromuscular Center, Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Copenhagen Neuromuscular Center</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 19, 2018</study_first_submitted>
  <study_first_submitted_qc>November 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2018</study_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Nicoline Løkken</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Mitochondrial Myopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

